FDA Update

October 2009
Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p11
The article reports on the warning of the Food and Drug Administration (FDA) to pharmaceutical companies regarding their misleading skincare advertisements in the U.S. FDA sent letters to several firms such as Johnson & Johnson, Galderma Laboratories LP and Allergan Inc., and it showed documented complaints like false advertising or baseless efficacy claims. Allergen received a harsher letter for its advertisement of the acne gel Aczone which is seen as misleading.


Related Articles

  • New Products.  // Dermatology Times;Jul2006, Vol. 27 Issue 7, p126 

    The article reports on various dermatological products. The Galderma Laboratories offers information about Clobex, a treatment for moderate-to severe psoriasis and other steroid responsive dermatoses, on its Web site. Meanwhile, the U.S. Food and Drug Administration has approved Allergan's...

  • Furrowed brows. Stein, Lisa // U.S. News & World Report;9/23/2002, Vol. 133 Issue 11, p18 

    Reports that the U.S. Food & Drug Administration has ordered Allergan, the maker of Botox, to pull so-called misleading television advertisements. Use of Botox, which is made from a food toxin, to smooth wrinkles between the eyebrows; Idea that the commercials make false claims about results...

  • No summer vacation for DDMAC staff.  // Medical Marketing & Media;Oct2009, Vol. 44 Issue 10, p11 

    The article reports on the warnings and letters issued by the U.S. Food and Drug Administration's (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) to drug companies for misleading marketing. Allergan Inc. received warning letters for a journal advertisement of the drug...

  • In brief….  // Cardiovascular Devices & Drugs;Jul2009, Vol. 15 Issue 7, p13 

    This section offers news briefs related to the U.S. pharmaceutical industry. A complete response letter was received by Allergan from the U.S. Food and Drug Administration (FDA) regarding Botox to treat upper limb spasticity in post-stroke adults. An FDA orphan drug designation was received by...

  • DDMAC losing patience. Friede, Arnold // Medical Marketing & Media;Oct2009, Vol. 44 Issue 10, p66 

    The article presents the author's views regarding the U.S. Food and Drug Administration's (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) letter to Allergan Inc. in August 2009. It notes that the warning letter to Allergan about a journal advertisement for Aczone from...

  • FDA ROUNDUP.  // MondayMorning;7/16/2012, Vol. 20 Issue 28, p1 

    The article presents the latest happenings within the U.S. Food and Drug Administration (FDA) as of July 2012. FDA has agreed to give priority status to its review of three new uses for the anticlotting drug Xarelto from Johnson & Johnson. FDA plans to provide medical device makers feedback...

  • Chain PHARMACY: REPORTERS Notebook.  // Drug Store News;8/1/2011, Vol. 33 Issue 10, p28 

    The article offers news briefs related to the U.S. pharmaceutical industry including Food and Drug Administration's (FDA) approval on a drug developed by Johnson & Johnson, the launching of Dr. Reddy's Labs' generic drug for hypertension, and FDA's approval on a drug made by Archimedes Pharma.

  • Tylenol's Headache. O'Rourke, Morgan // Risk Management (00355593);Jun2010, Vol. 57 Issue 5, p8 

    The article focuses on the Tylenol crisis of Johnson & Johnson and its subsidiary, McNeil Consumer Healthcare, which has led to a voluntary recall of their products. Recalled products include more than 40 varieties of children's and infant's liquid Tylenol, Motrin and Zytrec. Twenty different...

  • New Products.  // Dermatology Nursing;Feb2006, Vol. 18 Issue 1, p83 

    The article introduces several new dermatological products available in the market as of March 2006. Allergan Inc. has launched Prevage antioxidant cream to reduce fine lines and wrinkles. Galderama Laboratories has received approval of its MetroGel, a topical treatment for inflammatory lesions...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics